Tiziana Life Sciences is trading 5.09% down at $1.02, with no verified company-specific announcement identified for August 28, 2026.
- The latest listed announcement was an August 24 poster presentation on the Phase 2a BANYAN trial of intranasal foralumab.
- The broader market is only modestly higher, with no clear broad-market or sector explanation.
- The move may reflect normal volatility and profit-taking after recent weakness, but no specific cause is confirmed.